急性缺血性卒中静脉溶栓后辅助静脉阿加曲班或依替巴肽的疗效与安全性
这项3期、三组、适应性、单盲、随机对照试验在美国57个中心纳入514例发病3小时内接受静脉溶栓的急性缺血性卒中患者,随机接受静脉阿加曲班(59例)、依替巴肽(227例)或安慰剂(228例),均在溶栓启动后75分钟内给药。主要疗效终点90天效用加权改良Rankin量表评分均值:阿加曲班5.2±3.7、依替巴肽6.3±3.2、安慰剂6.8±3.0;阿加曲班优于安慰剂的后验概率0.002(后验均值差-1.51±0.51),依替巴肽优于安慰剂的后验概率0.041(后验均值差-0.50±0.29)。症状性颅内出血三组相似(阿加曲班4%、依替巴肽3%、安慰剂2%),但90天死亡率阿加曲班24%、依替巴肽12%,均高于安慰剂8%。
要点
- 静脉溶栓后75分钟内辅助阿加曲班或依替巴肽,90天效用加权mRS评分未优于安慰剂(阿加曲班5.2±3.7、依替巴肽6.3±3.2 vs 安慰剂6.8±3.0)。
- 90天死亡率阿加曲班24%、依替巴肽12%,均高于安慰剂8%。
- 症状性颅内出血36小时内三组相似:阿加曲班4%、依替巴肽3%、安慰剂2%。
- 研究纳入发病3小时内接受静脉溶栓者(70%阿替普酶、30%替奈普酶),44%接受血管内取栓。
- 作者结论:辅助阿加曲班或依替巴肽未减少卒中后残疾,且与死亡率升高相关。
适用人群与场景
- 发病3小时内接受静脉溶栓的急性缺血性卒中患者,在美国57个中心纳入。
- 全部患者接受静脉溶栓(70%阿替普酶、30%替奈普酶),225例(44%)接受血管内取栓。
处置流程与药物剂量
- 随机分配至静脉阿加曲班(59例)、依替巴肽(227例)或安慰剂(228例),均在溶栓启动后75分钟内给药。
研究设计与关键结果
- 3期、三组、适应性、单盲、随机对照试验,美国57个中心,514例发病3小时内接受静脉溶栓的急性缺血性卒中患者。
- 主要疗效终点90天效用加权改良Rankin量表评分(范围0~10,评分越高结局越好)均值:阿加曲班5.2±3.7、依替巴肽6.3±3.2、安慰剂6.8±3.0。
- 阿加曲班优于安慰剂的后验概率0.002(后验均值差-1.51±0.51);依替巴肽优于安慰剂的后验概率0.041(后验均值差-0.50±0.29)。
- 主要安全终点随机化后36小时内症状性颅内出血:阿加曲班4%、依替巴肽3%、安慰剂2%。
- 90天死亡率:阿加曲班24%、依替巴肽12%,均高于安慰剂8%。
证据类型、等级与局限
- 证据类型:3期、三组、适应性、单盲、随机对照试验。
对床旁实践的改变
- 作者结论:对发病3小时内接受静脉溶栓的急性缺血性卒中患者,辅助静脉阿加曲班或依替巴肽未减少卒中后残疾,且与死亡率升高相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Intravenous thrombolysis is a standard treatment of acute ischemic stroke. The efficacy and safety of combining intravenous thrombolysis with argatroban (an anticoagulant agent) or eptifibatide (an antiplatelet agent) are unclear.
METHODS: We conducted a phase 3, three-group, adaptive, single-blind, randomized, controlled clinical trial at 57 sites in the United States. Patients with acute ischemic stroke who had received intravenous thrombolysis within 3 hours after symptom onset were assigned to receive intravenous argatroban, eptifibatide, or placebo within 75 minutes after the initiation of thrombolysis. The primary efficacy outcome, the utility-weighted 90-day modified Rankin scale score (range, 0 to 10, with higher scores reflecting better outcomes), was assessed by means of centralized adjudication. The primary safety outcome was symptomatic intracranial hemorrhage within 36 hours after randomization.
RESULTS: A total of 514 patients were assigned to receive argatroban (59 patients), eptifibatide (227 patients), or placebo (228 patients). All the patients received intravenous thrombolysis (70% received alteplase, and 30% received tenecteplase), and 225 patients (44%) underwent endovascular thrombectomy. At 90 days, the mean (±SD) utility-weighted modified Rankin scale scores were 5.2±3.7 with argatroban, 6.3±3.2 with eptifibatide, and 6.8±3.0 with placebo. The posterior probability that argatroban was better than placebo was 0.002 (posterior mean difference in utility-weighted modified Rankin scale score, -1.51±0.51) and that eptifibatide was better than placebo was 0.041 (posterior mean difference, -0.50±0.29). The incidence of symptomatic intracranial hemorrhage was similar in the three groups (4% with argatroban, 3% with eptifibatide, and 2% with placebo). Mortality at 90 days was higher in the argatroban group (24%) and the eptifibatide group (12%) than in the placebo group (8%).
CONCLUSIONS: In patients with acute ischemic stroke treated with intravenous thrombolysis within 3 hours after symptom onset, adjunctive treatment with intravenous argatroban or eptifibatide did not reduce poststroke disability and was associated with increased mortality. (Funded by the National Institute of Neurological Disorders and Stroke; MOST ClinicalTrials.gov number, NCT03735979.).
参考来源
- Adeoye O, Broderick J, Derdeyn CP, et al. Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke. N Engl J Med. 2024. PMID: 39231343. doi:10.1056/NEJMoa2314779
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。